The Janssen Pharmaceutical Companies of Johnson & Johnson has ended the phase 3 Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation, also known as CREDENCE, based on the achievement of pre-specified efficacy criteria, the company reported.
The goal of the study is to assess whether Invokana (canagliflozin, Janssen Pharmaceuticals Inc.) has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in patients with type 2 diabetes mellitus, stage 2 or 3 CKD and macroalbuminuria.
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.
No commercial support for this activity.
Transplant Centers Resource Center
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.